[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:relapsing-remitting-multiple-sclerosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":52,"states":53},"Relapsing-Remitting Multiple Sclerosis",6,4,[8,16,23,29,36,44],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07667322","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis",[12],"Phase 1","RECRUITING","2026-08-03T01:02:27.992967Z","2026-07-05T20:59:06.676422Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05359653","Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.430631Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07011914","Care in Multiple Sclerosis (MS)",[],"2026-08-26T02:16:34.792807Z","2026-05-13T02:55:06.606152Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07510607","Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis",[33],"Phase 2","2026-08-26T02:16:48.735701Z","2026-05-05T02:43:28.715440Z",{"nct_id":37,"title":38,"phases":39,"status":41,"updated_at":42,"content_modified":43},"NCT06495593","Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis",[40],"Phase 4","ENROLLING_BY_INVITATION","2026-08-26T02:17:39.048487Z","2026-06-16T05:54:07.757786Z",{"nct_id":45,"title":46,"phases":47,"status":49,"updated_at":50,"content_modified":51},"NCT06700343","Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)",[48],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:20:46.845106Z","2026-05-05T02:43:28.175690Z",[],[54],{"state":55,"count":5,"slug":56},"California","california"]